Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net loss	$ (26,616)	$ (10,322)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	2	3
In-process research and development	30,117	0
Noncash transaction costs shared with Seneca	(135)	0
Noncash lease expense	166	143
Gain on forgiveness of PPP loan	(279)	0
Accretion of debt discount and non-cash interest expense	2,339	202
Loss on issuance of LBS Series 1 Preferred Stock	1,881	0
Loss on issuance of secured debt	686	841
Loss on issuance of warrants	3,247	0
Change in fair value of warrant liabilities	(23,033)	(38)
Change in fair value of share liability	(91)	0
Stock-based compensation	1,891	2,014
Other	(192)	0
Changes in operating assets and liabilities:
Trade and other receivables	84	(59)
Prepaid and other assets	(1,157)	89
Accounts payable and accrued liabilities	(2,395)	1,006
Accrued compensation	(1,120)	1,494
Operating lease liabilities	(168)	(141)
Net cash used in operating activities	(14,773)	(4,768)
Cash flows from investing activities:
Cash acquired in connection with the Merger	3,279	0
Acquisition related costs paid	(3,333)	0
Purchases of property and equipment	0	(6)
Net cash provided by (used in) investing activities	(54)	(6)
Cash flows from financing activities:
Payments on debt	(1,433)	(27)
Proceeds from issuance of debt	1,250	379
Proceeds from the issuance of related party debt	0	450
Proceeds from issuance of LBS Series 1 Preferred Stock	19,900	0
Proceeds from issuance of common stock and warrants	5,209	1,175
Redemption of warrants	(99)	0
Payment of equity issuance costs	(67)	0
Payment of debt issuance costs	(151)	(87)
Net cash provided by financing activities	24,609	1,890
Net increase (decrease) in cash, cash equivalents and restricted cash	9,782	(2,884)
Cash, cash equivalents and restricted cash, beginning of period	739	3,623
Cash, cash equivalents and restricted cash, end of period	10,521	739
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:
Cash and cash equivalents	10,495	713
Restricted cash	26	26
Total cash, cash equivalents and restricted cash	10,521	739
Supplemental disclosure of cash flows:
Interest paid	64	55
Supplemental disclosures of non-cash investing and financing activities:
Equity issuance costs included in accounts payable	0	41
Transaction costs shared with Seneca	135	0
Acquisition costs related to stock issuance	1,184	0
Issuance of common stock to former Seneca stockholders	28,728	0
Conversion of LBS Series C Preferred stock into common stock	9,503	0
Net assets acquired in the Merger	2	0
Acquisition related vesting of RSU’s assumed in the Merger	41	0
Acquisition related fair value change in warrant liability assumed in the Merger	51	0
Debt discount for issuance of warrants	0	29
Issuance of common stock for the cashless exercise of warrants	1,689	0
Deferred transaction costs in accounts payable and accrued liabilities	0	1,817
Issuance of common stock for settlement of trade payable	0	9
Debt issuance costs included in accounts payable	$ 0	$ 61